almagate has been researched along with Wet Macular Degeneration in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (3.70) | 29.6817 |
| 2010's | 26 (96.30) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| AbouChehade, JE; Bakri, SJ; Dalvin, LA; Damento, GM; Garcia, M; Hodge, DO; Iezzi, R; Meissner, I; Shah, SM; Starr, MR | 1 |
| Chrapek, O; Demlová, R; Dubská, Z; Kandrnal, V; Kolář, P; Pitrová, Š; Řehák, J; Rencová, E; Říhová, B; Rozsíval, P; Studnička, J | 1 |
| Ishibashi, T | 1 |
| Burova, M; Dusová, J; Jarkovský, J; Kandrnal, V; Marák, J; Rencová, E; Rozsíval, P; Studnička, J | 1 |
| Bron, AM; Creuzot-Garcher, C; Isaico, R; Kauffmann, Y; Lefebvre, A | 1 |
| Boyer, DS; Goldbaum, M; Leys, AM; Starita, C | 1 |
| Kurihara, T; Nagai, N; Okamoto, T; Ozawa, Y; Shinoda, H; Tsubota, K | 1 |
| Hoguet, A; Parrish, RK | 1 |
| Losada, M; Manresa, N; Mulero, J; Zafrilla, P | 2 |
| Arakawa, A; Inoue, M; Ishibashi, T; Kadonosono, K; Yamane, S | 1 |
| Diplotti, L; Kuppermann, BD; Lanzetta, P; Samassa, F; Santarelli, M; Veritti, D | 1 |
| Agostini, H; Bauer-Steinhusen, U; Ehlken, C; Hasanbasic, Z; Mueller, S; Wilke, T | 1 |
| Becker, M; Brynskov, T; Freiberg, FJ; Michels, S; Munk, MR; Sørensen, TL; Wirth, MA; Wolf, S | 1 |
| Bloch, SB; Larsen, M | 1 |
| Campbell, S; Friberg, TR; Goldbaum, M; Patel, S; Tolentino, M; Weber, P | 1 |
| Horsley, MB; Kahook, MY; Mandava, N; Maycotte, MA | 1 |
| Manfreda, I; Uhlig, CE | 1 |
| Giacomelli, G; Menchini, F; Murro, V; Novielli, N; Virgili, G | 1 |
| Matthé, E; Sandner, D | 1 |
| Qiu, KL; Zhang, MZ | 1 |
| de Oliveira Dias, JR; Farah, ME; Magalhães, O; Maia, M; Penha, FM; Rodrigues, EB | 1 |
| Heimann, H; Pauleikhoff, D; Wachtlin, J; Yang, Y | 1 |
| Ansari-Shahrezaei, S; Binder, S; Haas, P; Hagen, S; Krebs, I; Schmid-Kubista, KE | 1 |
| Lanzetta, P; Sarao, V; Veritti, D | 1 |
| Bogaert, P; Cruess, AF; Kaiser, PK; Kelly, SP; Khunti, K | 1 |
| Huber, S; Kieselbach, GF; Kirchmair, R; Kralinger, MT; Zehetner, C | 1 |
6 review(s) available for almagate and Wet Macular Degeneration
| Article | Year |
|---|---|
Advances in pharmacotherapy for wet age-related macular degeneration.
Topics: Angiogenesis Inhibitors; Aptamers, Nucleotide; Bevacizumab; Humans; Platelet-Derived Growth Factor; Protein-Tyrosine Kinases; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Vascular Endothelial Growth Factor A; Wet Macular Degeneration | 2015 |
[Treatment of wet age-related macular degeneration with vascular endothelial growth factor. A survey of a Cochrane review].
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Evidence-Based Medicine; Humans; Porphyrins; Ranibizumab; Treatment Outcome; Vascular Endothelial Growth Factor A; Wet Macular Degeneration | 2009 |
Pharmacological treatments for neovascular age-related macular degeneration: can mixed treatment comparison meta-analysis be useful?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Blindness; Combined Modality Therapy; Drug Administration Schedule; Humans; Meta-Analysis as Topic; Photochemotherapy; Photosensitizing Agents; Porphyrins; Ranibizumab; Verteporfin; Wet Macular Degeneration | 2011 |
Cytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Cytokines; Drug Therapy, Combination; Eye Proteins; Fibroblast Growth Factor 2; Hepatocyte Growth Factor; Humans; Infliximab; Intravitreal Injections; Molecular Targeted Therapy; Nerve Growth Factors; Platelet-Derived Growth Factor; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Serpins; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Wet Macular Degeneration | 2011 |
Neovascular age-related macular degeneration.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Humans; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Vascular Endothelial Growth Factor A; Wet Macular Degeneration | 2012 |
Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Drug and Narcotic Control; Drug Approval; European Union; Humans; Legislation, Drug; Off-Label Use; Prescription Drugs; Ranibizumab; Risk Assessment; Vascular Endothelial Growth Factor A; Wet Macular Degeneration | 2012 |
6 trial(s) available for almagate and Wet Macular Degeneration
| Article | Year |
|---|---|
[Wet form age-related macular degeneration two years treatment results using anti VEGF drugs].
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Drug Administration Schedule; Female; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Humans; Male; Middle Aged; Ranibizumab; Retrospective Studies; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Wet Macular Degeneration | 2013 |
Effect of pegaptanib sodium 0.3 mg intravitreal injections (Macugen) in intraocular pressure: posthoc analysis from V.I.S.I.O.N. study.
Topics: Adult; Angiogenesis Inhibitors; Aptamers, Nucleotide; Double-Blind Method; Female; Humans; Intraocular Pressure; Intravitreal Injections; Male; Middle Aged; Tonometry, Ocular; Vascular Endothelial Growth Factor A; Wet Macular Degeneration | 2014 |
Patient Preferences in the Treatment of Neovascular Age-Related Macular Degeneration: A Discrete Choice Experiment.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Aptamers, Nucleotide; Bevacizumab; Choice Behavior; Female; Humans; Intravitreal Injections; Male; Patient Preference; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Surveys and Questionnaires; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Wet Macular Degeneration | 2016 |
Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study.
Topics: Aged; Angiogenesis Inhibitors; Aptamers, Nucleotide; Cornea; Female; Humans; Macular Degeneration; Male; Middle Aged; Prospective Studies; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Wet Macular Degeneration | 2010 |
Comparing treatment of neovascular age-related macular degeneration with sequential intravitreal Avastin and Macugen versus intravitreal mono-therapy--a pilot study.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Contrast Sensitivity; Double-Blind Method; Drug Therapy, Combination; Female; Fluorescein Angiography; Follow-Up Studies; Humans; Intravitreal Injections; Male; Middle Aged; Pilot Projects; Prospective Studies; Retreatment; Vascular Endothelial Growth Factor A; Visual Acuity; Wet Macular Degeneration | 2011 |
Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Enzyme-Linked Immunosorbent Assay; Female; Humans; Intravitreal Injections; Macular Edema; Male; Postoperative Period; Preoperative Period; Prospective Studies; Ranibizumab; Vascular Endothelial Growth Factor A; Wet Macular Degeneration | 2013 |
15 other study(ies) available for almagate and Wet Macular Degeneration
| Article | Year |
|---|---|
Association of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy With Risk of Stroke, Myocardial Infarction, and Death in Patients With Exudative Age-Related Macular Degeneration.
Topics: Aged; Aptamers, Nucleotide; Cause of Death; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Intravitreal Injections; Macula Lutea; Male; Minnesota; Myocardial Infarction; Prognosis; Retrospective Studies; Risk Assessment; Risk Factors; Stroke; Survival Rate; Time Factors; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Wet Macular Degeneration | 2019 |
Cost and effectiveness of therapy for wet age-related macular degeneration in routine clinical practice.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Cost-Benefit Analysis; Female; Follow-Up Studies; Health Care Costs; Humans; Male; Middle Aged; Photochemotherapy; Photosensitizing Agents; Porphyrins; Ranibizumab; Retrospective Studies; Treatment Outcome; Verteporfin; Visual Acuity; Wet Macular Degeneration | 2013 |
Maintenance therapy with pegaptanib sodium for neovascular age-related macular degeneration: an exploratory study in Japanese patients (LEVEL-J study).
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Aptamers, Nucleotide; Asian People; Female; Fluorescein Angiography; Humans; Intraocular Pressure; Intravitreal Injections; Japan; Male; Middle Aged; Prospective Studies; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Wet Macular Degeneration | 2013 |
[Relationship between intravitreal anti-VEGF therapy and subretinal hemorrhage in patients with exudative age-related macular degeneration].
Topics: Aged, 80 and over; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Female; Humans; Incidence; Intravitreal Injections; Male; Ranibizumab; Retinal Hemorrhage; Retrospective Studies; Vascular Endothelial Growth Factor A; Wet Macular Degeneration | 2014 |
Intraoperative and fluorescein angiographic findings of a secondary macular hole associated with age-related macular degeneration treated by pars plana vitrectomy.
Topics: Aged; Aptamers, Nucleotide; Basement Membrane; Coloring Agents; Epiretinal Membrane; Fluorescein Angiography; Humans; Indocyanine Green; Intraoperative Period; Male; Retinal Perforations; Vascular Endothelial Growth Factor A; Vitrectomy; Wet Macular Degeneration | 2014 |
Unexpected hypotony after glaucoma drainage implant surgery associated with anti-vascular endothelial growth factor treatment.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Female; Glaucoma Drainage Implants; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Intravitreal Injections; Ocular Hypotension; Postoperative Complications; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Vascular Endothelial Growth Factor A; Wet Macular Degeneration | 2015 |
Influence of anti-VEGF about cardiovascular biomarkers in age related macular degeneration.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Atherosclerosis; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Female; Fibrinogen; Homocysteine; Humans; Lipids; Macular Degeneration; Male; Middle Aged; Ranibizumab; Risk Factors; Vascular Endothelial Growth Factor A; Wet Macular Degeneration | 2015 |
Long-term outcome of intravitreal pegaptanib sodium as maintenance therapy in Japanese patients with neovascular age-related macular degeneration.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Aptamers, Nucleotide; Asian People; Female; Follow-Up Studies; Humans; Intravitreal Injections; Japan; Maintenance Chemotherapy; Male; Prospective Studies; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Visual Acuity; Wet Macular Degeneration | 2015 |
EFFECT OF PEGAPTANIB AND RANIBIZUMAB ON PLASMA AND VITREOUS HOMOCYSTEINE IN PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Aptamers, Nucleotide; Exudates and Transudates; Female; Homocysteine; Humans; Intravitreal Injections; Male; Middle Aged; Nephelometry and Turbidimetry; Ranibizumab; Vascular Endothelial Growth Factor A; Vitreous Body; Wet Macular Degeneration | 2015 |
LOW ENDOPHTHALMITIS RATES AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS IN AN OPERATION ROOM: A Retrospective Multicenter Study.
Topics: Angiogenesis Inhibitors; Aptamers, Nucleotide; Bevacizumab; Denmark; Endophthalmitis; Equipment Contamination; Eye Infections, Bacterial; Follow-Up Studies; Humans; Incidence; Intravitreal Injections; Operating Rooms; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retrospective Studies; Risk Factors; Switzerland; Time Factors; Vascular Endothelial Growth Factor A; Wet Macular Degeneration | 2017 |
Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Female; Humans; Injections; Male; Nerve Fibers; Optic Disk; Ranibizumab; Retinal Ganglion Cells; Retreatment; Retrospective Studies; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Vitreous Body; Wet Macular Degeneration | 2010 |
[Non-response and change of anti-VEGF agent in exsudative age-related macular degeneration].
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Combined Modality Therapy; Fluorescein Angiography; Humans; Injections, Intraocular; Male; Photochemotherapy; Ranibizumab; Retina; Retreatment; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body; Wet Macular Degeneration | 2010 |
[Monotherapy of exudative age-related macular degeneration with ranibizumab in patients at cardiovascular risk. Advantages of ranibizumab compared to a combination with pegaptanib].
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Choroidal Neovascularization; Coronary Artery Bypass; Coronary Disease; Drug Therapy, Combination; Female; Humans; Intravitreal Injections; Male; Myocardial Infarction; Ranibizumab; Retrospective Studies; Risk Factors; Stents; Stroke; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Wet Macular Degeneration | 2011 |
The effect of image quality on retinal nerve fiber layer measurement in Stratus OCT.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Humans; Intravitreal Injections; Nerve Fibers; Optic Disk; Ranibizumab; Retinal Ganglion Cells; Retreatment; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Wet Macular Degeneration | 2011 |
[Differences in the treatment of exudative age-related macular degeneration in Germany and Great Britain].
Topics: Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Cross-Cultural Comparison; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Costs; Germany; Guideline Adherence; Health Care Costs; Health Expenditures; Humans; Intravitreal Injections; National Health Programs; Ranibizumab; State Medicine; United Kingdom; Vascular Endothelial Growth Factor A; Wet Macular Degeneration | 2011 |